journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Musculoskeletal Disease

journal
https://www.readbyqxmd.com/read/29619094/foot-osteoarthritis-latest-evidence-and-developments
#1
REVIEW
Edward Roddy, Hylton B Menz
Foot osteoarthritis (OA) is a common problem in older adults yet is under-researched compared to knee or hand OA. Most existing studies focus on the first metatarsophalangeal joint, with evidence relating to midfoot OA being particularly sparse. Symptomatic radiographic foot OA affects 17% of adults aged 50 years and over. The first metatarsophalangeal joint is most commonly affected, followed by the second cuneometatarsal and talonavicular joints. Epidemiological studies suggest the existence of distinct first metatarsophalangeal joint and polyarticular phenotypes, which have differing clinical and risk factor profiles...
April 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29619093/aromatase-inhibitors-are-associated-with-a-higher-fracture-risk-than-tamoxifen-a-systematic-review-and-meta-analysis
#2
REVIEW
Olivia L Tseng, John J Spinelli, Carolyn C Gotay, Wan Y Ho, Mary L McBride, Martin G Dawes
Background: In this paper, our aim was to systematically evaluate published evidence of bone fracture risk associated with tamoxifen and aromatase inhibitors in women aged 65 and under, and diagnosed with nonmetastatic breast cancer. Methods: We comprehensively searched MEDLINE, EMBASE and CINAHL databases from January 1997 through May 2015, and reference lists of the selected articles to identify English-language randomized controlled trials and cohort studies of fracture risk...
April 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29492111/efficacy-and-safety-of-sarilumab-in-patients-with-active-rheumatoid-arthritis
#3
REVIEW
Delilah McCarty, April Robinson
The mainstay of rheumatoid arthritis (RA) treatment involves the use of medications that slow disease progression and reduce inflammation. Inadequate treatment responses and intolerances to conventional RA treatment have led to the development of biologic agents for the management of moderate-to-severe disease activity. Interleukin-6 (IL-6) inhibition is one of the targets for biologic activity in RA treatment. IL-6 is found in excess in the synovial fluid and contributes to joint erosion through its action on osteoclast cells...
March 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29387178/intra-articular-hyaluronan-injections-for-the-treatment-of-osteoarthritis-perspective-for-the-mechanism-of-action
#4
Nicolas S Piuzzi, Ronald J Midura, George F Muschler, Vincent C Hascall
No abstract text is available yet for this article.
February 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29387177/management-of-primary-sj%C3%A3-gren-s-syndrome-recent-developments-and-new-classification-criteria
#5
REVIEW
Nicoletta Del Papa, Claudio Vitali
For many years primary Sjögren's syndrome (pSS) has been considered an orphan disease, since no specific therapies were recognized as being capable of contrasting the development and progression of this disorder. The treatment of oral and ocular features, as well as of the systemic organ involvement, has been entrusted to the joint management of different subspecialty physicians, like ophthalmologists, otolaryngologists, dentists and rheumatologists. These latter subspecialty doctors are usually more involved in the treatment of systemic extraglandular involvement and, to do it, they have long been using the conventional therapies borrowed by the treatment schedules adopted in other systemic autoimmune diseases...
February 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29387176/investigational-therapies-targeting-the-granulocyte-macrophage-colony-stimulating-factor-receptor-%C3%AE-in-rheumatoid-arthritis-focus-on-mavrilimumab
#6
REVIEW
Andrew D Cook, John A Hamilton
Mavrilimumab (formerly CAM-3001) is a high-affinity, immunoglobulin G4 monoclonal antibody (mAb) against the granulocyte macrophage colony-stimulating factor (GM-CSF) receptor-α chain. Phase I and II trials in patients with rheumatoid arthritis (RA) treated with mavrilimumab have shown encouraging results with respect to both safety and efficacy. No significant adverse events have so far been noted. The trials have demonstrated significant clinical benefit, meeting primary endpoints. Furthermore, for RA patients treated with mavrilimumab, who were tumour necrosis factor (TNF) inhibitor-inadequate responders, there are encouraging preliminary data indicating benefit and identifying potential biomarkers predictive of patients likely to find benefit...
February 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29290763/a-narrative-review-on-the-difficulties-associated-with-fibromyalgia-diagnosis
#7
REVIEW
Dinesh Kumbhare, Sara Ahmed, Scott Watter
Fibromyalgia presents a clinical enigma as its pathophysiology is not well understood and its symptoms are nonspecific and overlap with many disorders, making its diagnosis a challenge for clinicians and researchers. Efforts have been made to develop a set of diagnostic criteria for this disorder. However, these criteria rely heavily on expert clinician opinion and produce a large heterogeneity within the diagnosed population. With no present specific technique reflecting the underlying pathophysiology of fibromyalgia, a definitive diagnosis of fibromyalgia remains elusive...
January 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29290762/an-autumn-tale-geriatric-rheumatoid-arthritis
#8
REVIEW
Senol Kobak, Cemal Bes
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by erosive arthritis and systemic organ involvement. The disease may affect all ages and both sexes; usually it is seen in young women aged 25-45. Recent studies have shown that RA is among the most common inflammatory disease in older age groups. While elderly-onset rheumatoid arthritis (EORA) is still discussed in the literature, it is generally accepted as a disease beginning after 65 years of age. Compared with young-onset rheumatoid arthritis (YORA), it was found that EORA had different characteristics...
January 2018: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29201156/evidence-based-management-of-raynaud-s-phenomenon
#9
REVIEW
Ariane L Herrick
Raynaud's phenomenon (RP) is relevant to the rheumatologist because it may signify an underlying connective tissue disease and also because it can be very challenging to treat, especially when it has progressed to digital ulceration or critical ischaemia. This review article discusses diagnosis (does this patient have an underlying connective tissue disease?), including the role for nailfold capillaroscopy, and treatment. Management of 'uncomplicated' RP is first described and then treatment of RP complicated by progression to digital ulceration or critical ischaemia, highlighting recent advances (including phosphodiesterase type 5 inhibition, and endothelin 1 receptor antagonism) and the evidence base underpinning these...
December 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29201155/critical-issues-and-current-challenges-in-osteoporosis-and-fracture-prevention-an-overview-of-unmet-needs
#10
REVIEW
Willem F Lems, Hennie G Raterman
Osteoporosis is a silent disease with increasing prevalence due to the global ageing population. Decreased bone strength and bone quality is the hallmark of osteoporosis which leads to an increased risk of fragility fractures in elderly. It has been estimated that approximately ~50% of women will suffer during their lifetime from an osteoporotic fracture. This must be considered as a major health concern, as it has previously been established that fragility fracture has been associated with decreased quality of life due to increased disability, more frequent hospital admission and most importantly, osteoporotic fractures have been related to an augmented mortality risk...
December 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29344111/corrigendum
#11
(no author information available yet)
[This corrects the article DOI: 10.1177/1759720X17729641.].
November 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/29344110/anti-interleukin-and-interleukin-therapies-for-psoriasis-current-evidence-and-clinical-usefulness
#12
REVIEW
Ya-Chu Tsai, Tsen-Fang Tsai
Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24, IL-27, IL-33, IL-35, IL-37, and IL-38)...
November 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28974989/rituximab-biosimilar-in-rheumatoid-arthritis-an-enhanced-evidence-assessment-to-evaluate-equivalence-with-the-originator-based-on-network-meta-analysis
#13
Marco Chiumente, Andrea Messori
No abstract text is available yet for this article.
October 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28974988/sclerostin-antibodies-in-osteoporosis-latest-evidence-and-therapeutic-potential
#14
REVIEW
Michael R McClung
Sclerostin is an osteocyte-derived glycoprotein that inhibits Wnt/β-catenin signaling and activation of osteoblast function, thereby inhibiting bone formation. It plays a vital role in the regulation of skeletal growth. In adults, sclerostin secretion is modulated by skeletal loading (increased secretion with immobilization; less with weight bearing) and by hormonal/cytokine actions on the osteocyte. Sclerostin deficiency syndromes in humans and animals are characterized by high bone mass of normal quality...
October 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28974987/sustained-remission-in-rheumatoid-arthritis-latest-evidence-and-clinical-considerations
#15
REVIEW
Sofia Ajeganova, Tom Huizinga
Sustained remission is an ultimate treatment goal in the management of patients with rheumatoid arthritis (RA). Historically the frequency of sustained remission was low but the frequency of achieved sustained remission is increasing over time. The last years' clinical studies of tight control targeted treatment and intervention trials of early use of intensive strategy suggest that these treatment strategies are associated with higher rates of sustained remission. Achievement of sustained remission, in particular but not limited to early sustained remission, can provide tapering and stopping disease-modifying antirheumatic drugs (DMARDs)...
October 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28932293/intra-articular-hyaluronic-acid-in-the-treatment-of-knee-osteoarthritis-a-canadian-evidence-based-perspective
#16
REVIEW
Mohit Bhandari, Raveendhara R Bannuru, Eric M Babins, Johanne Martel-Pelletier, Moin Khan, Jean-Pierre Raynauld, Renata Frankovich, Deanna Mcleod, Tahira Devji, Mark Phillips, Emil H Schemitsch, Jean-Pierre Pelletier
Osteoarthritis (OA) is a chronic condition characterized by a loss of joint cartilage and is a major cause of disability in Canada, with an estimated CN$195 billion annual cost. Knee OA leads to persistent pain and loss of function, and treatment goals primarily focus on symptom relief and retention of function. Intra-articular hyaluronic acid (IAHA) has therapeutic benefits, and numerous recently published meta-analyses (MAs) and commentaries have highlighted new evidence on the role of IAHA therapy for knee OA...
September 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28932292/methotrexate-blood-pressure-and-markers-of-arterial-function-in-patients-with-rheumatoid-arthritis-a-repeated-cross-sectional-study
#17
Arduino A Mangoni, Leena R Baghdadi, E Michael Shanahan, Michael D Wiese, Sara Tommasi, David Elliot, Richard J Woodman
BACKGROUND: Methotrexate (MTX) treatment in rheumatoid arthritis (RA) has been associated with lower cardiovascular risk compared to other disease-modifying antirheumatic drugs (DMARDs). We sought to identify whether the MTX-associated cardioprotection involves changes in blood pressure (BP) and/or arterial function. METHODS: Clinic and 24-hour peripheral and central systolic and diastolic BP (SBP and DBP), augmentation index (AIx), pulse wave velocity (PWV) and plasma asymmetric dimethylarginine (ADMA) were assessed in RA patients on stable treatment with either MTX ± other DMARDs (MTX group, n = 56, age 61 ± 13 years, 70% females) or other DMARDs (non-MTX group, n = 30, age 63 ± 12 years, 76% females)...
September 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28835779/tumor-necrosis-factor-%C3%AE-tnf%C3%AE-inhibitors-in-the-treatment-of-nonradiographic-axial-spondyloarthritis-current-evidence-and-place-in-therapy
#18
REVIEW
Valeria Rios Rodriguez, Denis Poddubnyy
Nonradiographic axial spondyloarthritis (SpA) and radiographic SpA (also known as ankylosing spondylitis) are currently considered as two stages or forms of one disease (axial SpA). The treatment with tumor necrosis factor-α (TNFα) inhibitors has been authorized for years for ankylosing spondylitis. In recent years, most of the anti-TNFα agents have also been approved for the treatment of nonradiographic axial SpA by the European Medicines Agency (EMA) and similar authorities in many countries around the world (but not in the US), increasing the number of possible therapies for this indication...
August 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28835778/effectiveness-of-intra-articular-therapies-in-osteoarthritis-a-literature-review
#19
REVIEW
Peter Wehling, Christopher Evans, Jana Wehling, William Maixner
Osteoarthritis is a painful, chronic disease with widespread burden on patients, communities, health and social care systems. Conservative therapies, such as nonpharmacological interventions, systemic drug treatment and intra-articular therapies are used before resorting to surgery; nonetheless, disease control often remains inadequate. Recent advances in osteoarthritis management have aimed to provide greater variety of treatment options. Here, we summarize a targeted literature review evaluating efficacy and safety of intra-articular therapies for osteoarthritis...
August 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28717403/the-potential-role-of-adult-stem-cells-in-the-management-of-the-rheumatic-diseases
#20
REVIEW
Tiziana Franceschetti, Cosimo De Bari
Adult stem cells are considered as appealing therapeutic candidates for inflammatory and degenerative musculoskeletal diseases. A large body of preclinical research has contributed to describing their immune-modulating properties and regenerative potential. Additionally, increasing evidence suggests that stem cell differentiation and function are disrupted in the pathogenesis of rheumatic diseases. Clinical studies have been limited, for the most part, to the application of adult stem cell-based treatments on small numbers of patients or as a 'salvage' therapy in life-threatening disease cases...
July 2017: Therapeutic Advances in Musculoskeletal Disease
journal
journal
42615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"